Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (481-490 of 594) with videos related to

Pageof 60
Sort By:
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Cancer|October 21, 2017
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinomaFrederico O Gleber-Netto, Mei Zhao, Sanchit Trivedi, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
JCI Insight|August 16, 2020
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunityKathleen M McAndrews, Dara P Dowlatshahi, Jianli Dai, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 10, 2023
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancerHope Feldman, Boris Sepesi, Cheuk H Leung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancerBenjamin J Moeller, Vishal Rana, Blake A Cannon, et al.
International Journal of Radiation Oncology, Biology, Physics|February 23, 2010
Prospective imaging assessment of mortality risk after head-and-neck radiotherapyBenjamin J Moeller, Vishal Rana, Blake A Cannon, et al.
Pageof 60

Showing results (481-490 of 594) with videos related to

Sort By:
Pageof 60
Genome Medicine|October 5, 2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 1, 2023
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In SituAnne E O'Shea, Guy T Clifton, Na Qiao, et al.
JAMA Oncology|September 30, 2018
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical TrialErminia Massarelli, William William, Faye Johnson, et al.
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Cancer|October 21, 2017
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinomaFrederico O Gleber-Netto, Mei Zhao, Sanchit Trivedi, et al.
Journal for Immunotherapy of Cancer|October 6, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trialMaliazurina B Saad, Eman Showkatian, Vivek Verma, et al.
JCI Insight|August 16, 2020
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunityKathleen M McAndrews, Dara P Dowlatshahi, Jianli Dai, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 10, 2023
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancerHope Feldman, Boris Sepesi, Cheuk H Leung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancerBenjamin J Moeller, Vishal Rana, Blake A Cannon, et al.
International Journal of Radiation Oncology, Biology, Physics|February 23, 2010
Prospective imaging assessment of mortality risk after head-and-neck radiotherapyBenjamin J Moeller, Vishal Rana, Blake A Cannon, et al.
Pageof 60